Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latex-containing device reg's applicability to polymers should be clarified -- Convatec.

This article was originally published in The Gray Sheet

Executive Summary

LATEX-CONTAINING DEVICE RULE'S APPLICABILITY TO POLYMERS that certain latex proteins should be clarified by FDA, Bristol-Myers Squibb subsidiary Convatec says in recent comments to the agency. Commenting on a June 24 proposed rule, Convatec asks FDA to state whether restrictions proposed in the reg apply to devices that do not list latex as an ingredient of the product but that nonetheless contain latex protein polymers.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel